NM_015474.4:c.1411-2A>G
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_015474.4(SAMHD1):c.1411-2A>G variant causes a splice acceptor, intron change. The variant allele was found at a frequency of 0.00000187 in 1,601,060 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_015474.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- Aicardi-Goutieres syndrome 5Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, PanelApp Australia, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, G2P
- Moyamoya diseaseInheritance: AR Classification: STRONG Submitted by: Genomics England PanelApp
- Aicardi-Goutieres syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial chilblain lupusInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- chilblain lupus 2Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- chilblain lupusInheritance: AD Classification: NO_KNOWN Submitted by: Illumina
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| SAMHD1 | NM_015474.4 | c.1411-2A>G | splice_acceptor_variant, intron_variant | Intron 12 of 15 | ENST00000646673.2 | NP_056289.2 | ||
| SAMHD1 | NM_001363729.2 | c.1411-2A>G | splice_acceptor_variant, intron_variant | Intron 12 of 14 | NP_001350658.1 | |||
| SAMHD1 | NM_001363733.2 | c.1411-2A>G | splice_acceptor_variant, intron_variant | Intron 12 of 15 | NP_001350662.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SAMHD1 | ENST00000646673.2 | c.1411-2A>G | splice_acceptor_variant, intron_variant | Intron 12 of 15 | NM_015474.4 | ENSP00000493536.2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152158Hom.: 0 Cov.: 32 show subpopulations
GnomAD4 exome AF: 6.90e-7 AC: 1AN: 1448902Hom.: 0 Cov.: 27 AF XY: 0.00000139 AC XY: 1AN XY: 721810 show subpopulations ⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
Age Distribution
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152158Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74336 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Canonical splice site variant predicted to result in an in-frame loss of the adjacent exon in a gene for which loss of function is a known mechanism of disease; Published functional studies demonstrate skipping of exon 13 and degradation of the SAMHD1 protein in cell lysates from an affected individual (PMID: 21402907); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 21633013, 31028937, 19525956, 28289923, 22461318, 34852373, 20301648, 21402907, 27943079)
Aicardi-Goutieres syndrome 5 Pathogenic:1Other:1
This sequence change affects an acceptor splice site in intron 12 of the SAMHD1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. This variant is present in population databases (rs515726141, gnomAD 0.0009%). Disruption of this splice site has been observed in individual(s) with cerebral vasculopathy and early onset of stroke (PMID: 21402907). ClinVar contains an entry for this variant (Variation ID: 126407). Studies have shown that disruption of this splice site results in skipping of exon 13, but is expected to preserve the integrity of the reading-frame (PMID: 21402907). For these reasons, this variant has been classified as Pathogenic.
Aicardi-Goutieres syndrome 5;C3280721:Chilblain lupus 2 Pathogenic:1
SAMHD1-related disorder Pathogenic:1
The SAMHD1 c.1411-2A>G variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in the homozygous state to be causative for autosomal recessive Aicardi-Goutiѐres syndrome (Xin et al. 2011. PubMed ID: 21402907, Crow. 2016. PubMed ID: 20301648). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Variants that disrupt the consensus splice acceptor site in SAMHD1 are expected to be pathogenic. This variant is interpreted as pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at